{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '57', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'study. Eight of the participants had RCC, 2 had NSCLC, 2 had endometrial cancer, and 1 had', 'melanoma. There were 2 DLTs at the dose of lenvatinib 24 mg/day + pembrolizumab 200 mg', 'IV Q3W (1 participant had Grade 3 arthralgia and another had Grade 3 fatigue); hence, this', 'was defined as the toxic dose. No DLTs were reported in the next 10 participants (expansion', 'part), all of whom received the lenvatinib 20 mg/day + pembrolizumab 200 mg Q3W dose.', 'Based on review of all of the clinical data from these 13 participants, the MTD and RP2D', 'were determined to be 20 mg of lenvatinib daily in combination with a fixed dose of 200 mg', 'of pembrolizumab given Q3W. Based on the promising antitumor efficacy and tolerable', 'safety profile seen in both the endometrial carcinoma and RCC expansion cohorts from', 'Study 111/KEYNOTE-146 [Makker, V., et al 2018], 2 Phase 3 studies have been initiated for', 'both of these tumor types, Study E7080-G000-309/KEYNOTE-775 and Study E7080-G000-', '307/KEYNOTE-581.', '4.3.2.2', 'Pembrolizumab Dosing', 'The rationale for the use of a fixed dose of pembrolizumab in participants with solid tumors', 'was based on the following:', 'Similar efficacy and safety of pembrolizumab when dosed at 2 mg/kg Q3W,', '10 mg/kg Q3W, or 10 mg/kg every 2 weeks in participants with melanoma and', 'NSCLC', 'Flat exposure-response relationships of pembrolizumab for both efficacy and safety in', 'the dose range of 2 mg/kg Q3W to 10 mg/kg Q3W', 'The lack of clinically relevant effect of tumor burden or indication on distribution', 'behavior of pembrolizumab (as assessed by the population pharmacokinetics [PopPK]', 'model)', 'Pharmacology data showing full target saturation in both systemic circulation', '(inferred from PK data) and tumor (inferred from physiologically based PK analysis)', 'at 200 mg Q3W', 'The choice of pembrolizumab 200 mg Q3W as an appropriate fixed dose was based on', 'simulations performed using the PopPK model of pembrolizumab, which showed the', 'following for a fixed dose of 200 mg Q3W:', 'Provide similar control of PK variability as weight-based dosing, with considerable', 'overlap in the distribution of exposures from the 200 mg Q3W fixed dose and', '2 mg/kg Q3W dose', 'Maintain individual participant exposures in the exposure range associated with', 'maximal efficacy response that was established in participants with melanoma and', 'NSCLC', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '58', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Result in individual participant exposures within a range that was well tolerated and', 'safe in participants with melanoma and NSCLC', 'Clinical data have shown meaningful improvement in benefit-risk, including OS, at 200 mg', 'Q3W across multiple indications. Additionally, a fixed-dose regimen simplified the dosing', 'regimen to be more convenient for physicians and to reduce the potential for dosing errors. A', 'fixed-dosing scheme also reduced complexity in the logistical chain at treatment facilities', 'and reduced wastage.', '4.4', 'Beginning and End of Study Definition', 'The overall study begins when the first participant (or their legally acceptable representative)', 'provides documented informed consent. The overall study ends when the last participant', 'completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the', 'participant is unable to be contacted by the investigator).', '4.4.1', 'Clinical Criteria for Early Study Termination', 'The clinical study may be terminated early if the extent (incidence and/or severity) of', 'emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population', 'as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular', 'study site(s) may be stopped due to insufficient compliance with the protocol, Good Clinical', 'Practice (GCP), and/or other applicable regulatory requirements, procedure-related problems', 'or an unacceptably high number of discontinuations or withdrawals due to administrative', 'reasons.', '5', 'STUDY POPULATION', 'Male and female participants with Stage IV NSCLC, who express PD-L1 (TPS 1%), have', 'received no systemic anticancer therapy for their Stage IV NSCLC, and are at least 18 years', 'of age will be enrolled in this study.', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '5.1', 'Inclusion Criteria', 'To be eligible for inclusion in this study, the participant must:', 'Type of Participant and Disease Characteristics', '1. Have a histologically or cytologically confirmed diagnosis of NSCLC.', 'Note: Mixed tumors will be categorized by the predominant cell type; if small-cell', 'elements are present, the participant is ineligible.', '2. Have Stage IV NSCLC (American Joint Committee on Cancer [AJCC], version 8).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}